9.30am | Registration | |
10.00am | Welcome to the meeting and introduction | James Rowe, Stuart Pickering-Brown & Jonathan Rohrer |
10.10am | LATE onset TDP-43 and tauopathies are not PART of FTLD | Johannes Attems (Newcastle University) |
10.30am | More than words: auditory perceptual changes in PPA | Chris Hardy (UCL) |
10.50am | Advanced neuroimaging in FTD: what can we learn from MEG, PET and 7T fMRI | Thomas Cope (University of Cambridge) |
11.10am | Coffee break | |
11.40am | Nuclear-cytoplasmic transport dysfunction in FTD/ALS : a direct role for the nuclear pore? | Sarah Mizielinska (King's College London) |
12.00pm | The role of prion-like spreading of tau in neurodegenerative disease | David Klenerman (University of Cambridge) |
12.20pm | Screening for modifiers of C9orf72 hexonucleotide repeat expansion | Teresa Niccoli (UCL) |
12.40pm | Lunch | |
1.40pm | Structure-based drug discovery for the development of FTD therapeutics | Paul Mortenson (Astex) |
2.00pm | Novel therapies for FTD | Olga Uspenskaya (Prevail) |
2.20pm | Coffee break | |
2.50pm | Current management strategies in FTD | Panel discussion with short talks from Anna Volkmer (UCL) and James Rowe (University of Cambridge) |
3.20pm | Alzheimer's Society ECR prizes - introduction and award | Hannah Mackay |
3.30pm | Basic Science Prize for Early Career UK FTD Researcher sponsored by the Alzheimer's Society | |
3.40pm | Clinical Science Prize for Early Career UK FTD Researcher sponsored by the Alzheimer's Society | |
3.50pm | Summary | |
4.00pm | Finish |
9.30am | Registration | |
10.00am | Welcome to the meeting and introduction | Stuart Pickering-Brown, Jonathan Rohrer & James Rowe |
10.10am | The MLSE | Peter Garrard (St Georgeu2019s Hospital London) |
10.30am | Functional Networks in Genetic FTD u2013 Susceptibility and Resilience | Tim Rittman (University of Cambridge) |
10.50am | Disease modelling approaches to FTD | Alexandra Young (UCL) |
11.10am | Coffee break | |
11.40am | Thereu2019s something wrong with my MAM; ER-mitochondria signaling and neurodegenerative diseases | Chris Miller (King's College London) |
12.00pm | C9orf72 FTD/ALS: mechanisms and therapeutics | Adrian Isaacs (UCL) |
12.20pm | Gene therapy approaches to ALS | Pam Shaw (Sheffield) |
12.40pm | Lunch | |
1.40pm | Novel therapies for GRN-related FTD | Robert Paul (Alector) |
2.00pm | Novel cell-based therapies for FTD | Johan Lundkvist (Alzecure) |
2.20pm | Coffee break | |
2.50pm | Improving the diagnostic pathway for patients with FTD | Panel discussion |
3.30pm | Basic Science Prize for Early Career UK FTD Researcher | |
3.40pm | Clinical Science Prize for Early Career UK FTD Researcher | |
3.50pm | Update on UK dementia initiatives | |
4.00pm | Finish |
9.30am | Registration | |
10.00am | Welcome to the meeting and introduction | Jonathan Rohrer, James Rowe & Stuart Pickering-Brown |
10.10am | Neuropsychological profiles in FTD and ALS-FTD | Jennifer Saxon (University of Manchester) |
10.30am | Novel PET ligands for imaging neurodegeneration | Ilan Rabiner (Imanova) |
10.50am | Staging systems in ALS - incorporating FTD and cognitive impairment | Ammar Al-Chalabi (King's College London) |
11.10am | Coffee break | |
11.40am | New models of tauopathy | Diane Hanger (King's College London) |
12.00pm | Modelling FTD with patient-derived iPSC-neurons | Selina Wray (UCL) |
12.20pm | Investigating protein degradation deficits in FTD | Gemma Lace-Costigan (Salford University) |
12.40pm | Lunch | |
1.40pm | Stereopure oligonucleotides as a therapeutic approach to rare neurological diseases | Michael Panzara (WAVE Life Sciences) |
2.00pm | The age of tau therapy u2013 from shadow to sunlight | Norbert u017dilka (Axon) |
2.20pm | Coffee break | |
2.50pm | Developing standards of care in the diagnosis and management of FTD | Panel discussion |
3.30pm | Basic Science Prize for Early Career UK FTD Researcher | |
3.40pm | Clinical Science Prize for Early Career UK FTD Researcher | |
3.50pm | Update on UK dementia initiatives, including IFGC update, and summary of day | |
4.00pm | Finish |
9.30am | Registration | |
10.00am | Welcome to the meeting and introduction | James Rowe, Stuart Pickering-Brown & Jonathan Rohrer |
10.10am | Tau PET imaging in PSP | James Rowe (University of Cambridge) |
10.30am | Imaging of subcortical structures and their connections in FTD | Martina Bocchetta (UCL) |
10.50am | Clinical, imaging and path features of TBK1 mutations in FTD and ALS | Jonathan Rohrer (UCL) |
11.10am | Coffee break | |
11.40am | Antisense and sense RNA foci derived from repeat expansions of C9orf72 have similar interactions but distinct expression patterns | Jonathan Cooper-Knock (University of Sheffield) |
12.00pm | Modelling C9orf72 dipeptide repeats: size matters | Sarah Ryan (University of Manchester) |
12.20pm | Genetic modifiers of CHMP2B | Sean Sweeny (University of York) |
12.40pm | Lunch | |
1.40pm | Development of the tau directed monoclonal antibody BMS-986168 for the treatment of PSP | Irfan Qureshi (BMS) |
2.00pm | O-GlcNAcase inhibition as potential treatment for tauopathies | Dirk Beher (Asceneuron) |
2.20pm | Coffee break | |
2.50pm | An update on ALS research in the last year | Chris Shaw (Kingu2019s College London) |
3.10pm | The new PSP criteria and an update on the PROSPECT study | Huw Morris (UCL) |
3.30pm | An update on UK dementia initiatives and the role of FTD, PSP, CBS and ALS in these initiatives | |
3.45pm | Finish |
9.30am | Registration | |
10.00am | Welcome to the meeting and introduction | Stuart Pickering-Brown, Jonathan Rohrer & James Rowe |
10.10am | Epidemiology of FTD - the PiPPIN study | Ian Coyle-Gilchrist (University of Cambridge) |
10.30am | CSF and serum biomarkers in FTD | Henrik Zetterberg (UCL) |
10.50am | Serum markers in MND and their relevance to FTD | Martin Turner (University of Oxford) |
11.10am | Coffee break | |
11.40am | Current therapeutic trials in FTD | Catherine Mummery (UCL) |
12.00pm | Novel tau therapeutics | Roger Lane (Isis Pharmaceuticals) |
12.20pm | Inflammatory PET imaging | Alex Gerhard (University of Manchester) |
12.40pm | Lunch | |
1.40pm | The role of TDP-43 in neurodegenerative disease | Tammaryn Lashley (UCL) |
2.00pm | Novel MND genes and their relevance to FTD | Kevin Talbot (University of Oxford) |
2.20pm | Coffee break | |
2.50pm | Updates in UK FTD research | |
3.15pm | Finish |
9.30am | Registration | |
10.00am | Welcome to the meeting and introduction | Jonathan Rohrer, James Rowe & Stuart Pickering-Brown |
10.10am | New findings in the genetics of C9orf72 | Stuart Pickering-Brown (University of Manchester) |
10.30am | Mechanisms of toxicity in C9FTD/ALS | Sarah Mizielinska (UCL) |
10.50am | Tau aggregation and neurodegeneration | Michel Goedert (University of Cambridge) |
11.10am | Coffee break | |
11.40am | Where are we with tau PET imaging of FTD? | Franklin Aigbirhio (University of Cambridge) |
12.00pm | Mechanisms of tau propagation | Suchira Bose (Lilly) |
12.20pm | The clinical stage HDAC inhibitor FRM-0334 induces progranulin in a variety of pre-clinical model systems | Holger Patzke (Forum Pharmaceuticals) |
12.40pm | Lunch | |
2.00pm | Physiological phenotyping of frontotemporal lobar degenerations | Jason Warren (UCL) |
2.20pm | What rating scales should we be using in clinical trials of FTD? | John Hodges (Neuroscience Research Australia) & Eneida Mioshi (University of Cambridge) |
2.40pm | What is the role of episodic memory in FTD? | Michael Hornberger (University of Cambridge) |
3.00pm | Coffee break | |
3.30pm | Updates on national and international dementia initiatives in relation to FTD research and summary of the day | |
4.00pm | Finish |
9.00am | Registration | |
9.30am | Welcome to the meeting and introduction | James Rowe, Stuart Pickering-Brown & Jonathan Rohrer |
9.50am | Next generation sequencing for dementia diagnosis | Simon Mead (UCL) |
10.10am | The molecular biology of C9orf72 | Adrian Isaacs (UCL) |
10.30am | Stem cell models of FTD | Selina Wray (UCL) |
10.50am | Coffee break | |
11.20am | PET imaging in FTD | Alex Gerhard (University of Manchester) |
11.40am | Preimplantation genetic diagnosis and genetic testing in FTD | Helen Murphy (Central Manchester University Hospitals NHS Foundation Trust) |
12.00pm | Lunch | |
1.00pm | GENFI u2013 the Genetic Frontotemporal Dementia Initiative | Jonathan Rohrer (UCL) |
1.20pm | The Tau Rx trial | Chris Kipps (University Hospital Southampton NHS Trust) |
1.40pm | What have we learned from PSP trials? | Nigel Leigh (University of Sussex) |
2.00pm | Coffee break | |
2.30pm | The PSP/CBS network | Huw Morris (UCL) |
2.50pm | Unique opportunities for integrated patient-based research in ALS and FTD | Martin Turner (University of Oxford) |
3.20pm | Summary of the day | |
3.30pm | Finish |
9.00am | Registration | |
9.30am | Welcome to the meeting and introduction | Stuart Pickering-Brown, Jonathan Rohrer & James Rowe |
9.50am | The new criteria for bvFTD and PPA u2013 how useful are they? | Matthew Jones (University of Manchester) |
10.10am | GWAS in FTD | Raffaele Ferrari (UCL) |
10.30am | A molecular biology perspective on FTD | John Hardy (UCL) |
10.50am | Coffee break | |
11.20am | What do we know so far about C9ORF72? | Huw Morris (University of Cardiff) |
11.40am | Genetic testing for FTD in the clinic | Simon Mead (UCL) |
12.00pm | Lunch | |
1.00pm | A systems neuroscience approach to FTD | James Rowe (University of Cambridge) |
1.20pm | Motor neurone disease and FTD u2013 do we need joint research platforms? | Kevin Talbot (University of Oxford) |
1.40pm | What do regional and national dementia registries mean for FTD? | Carol Brayne (University of Cambridge) |
2.00pm | Coffee break | |
2.30pm | What do patients and carers want from FTD research? | Jill Walton (Frontotemporal Dementia Support Group) |
2.50pm | Summary of the day | |
3.00pm | Finish |
9.30am | Registration | |
10.00am | Welcome to the meeting and introduction | Jonathan Rohrer, James Rowe & Stuart Pickering-Brown |
10.20am | Update on clinical aspects of FTD | Jason Warren (UCL) |
10.40am | Update on clinical trials | Nick Fox (UCL) |
11.00am | Update on imaging | James Rowe (University of Cambridge) |
11.20am | Coffee break | |
11.50am | Update on neuropsychology | Julie Snowden (University of Manchester) |
12.10pm | Update on the relationship of FTD with MND | Chris Shaw (Kingu2019s College London) |
12.30pm | Lunch | |
1.30pm | Update on genetics | Stuart Pickering-Brown (University of Manchester) |
1.50pm | Update on pathology | David Mann (University of Manchester) |
2.10pm | Update on animal models | Maria Spillantini (University of Cambridge) |
2.30pm | Coffee break | |
3.00pm | DENDRON and national dementia initiatives | Martin Rossor (UCL) |
3.20pm | Summary of the day | |
3.30pm | Finish |